Lead Product(s): SNA-based Therapeutics
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: Discovery Product Type: Undisclosed
Deal Size: $1,020.0 million Upfront Cash: $20.0 million
Deal Type: Collaboration August 02, 2021
Under the agreement, Ipsen will receive exclusive options to license SNA-based therapeutics arising from two collaboration programs for Huntington’s disease and Angelman syndrome.